Guggenheim analyst Michael Schmidt maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and adjusts the target price from $38 to $82.
According to TipRanks data, the analyst has a success rate of 50.5% and a total average return of 17.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
Following the presentation of initial Phase 1 findings for RMC-9805 in advanced pancreatic ductal adenocarcinoma patients at the EORTC-NCI-AACR Symposium, analysts have enhanced their confidence in the potential success of RMC-6036 in the current Phase 3 study for second-line pancreatic ductal adenocarcinoma, especially after considering the updated Phase 1/1b data disclosed recently.
Following recent clinical updates on '6236 and '9805 in PDAC presented at a major scientific meeting and an investor event, analysts have expressed their pleasure with the improvement seen in the updated Phase 1 data for '6236. The first reported median Overall Survival (mOS) data reinforces the potential of '6236 to change the treatment landscape in second line and beyond Pancreatic Ductal Adenocarcinoma (PDAC). Moreover, the First-in-Human (FIH) data of '9805 in PDAC is also met with a positive view, showcasing promising signs of clinical activity and a safety profile that exceeds initial expectations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Guggenheim分析師Michael Schmidt維持$Revolution Medicines (RVMD.US)$買入評級，並將目標價從38美元上調至82美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.5%，總平均回報率為17.0%。
此外，綜合報道，$Revolution Medicines (RVMD.US)$近期主要分析師觀點如下：
在歐洲癌症研究組織（EORTC）-新華保險（NCI）-美國抗癌協會（AACR）研討會上展示了愛文思控股RMC-9805在晚期胰腺導管腺癌患者中的初級1期研究結果後，分析師對當前第3期研究中針對第二線胰腺導管腺癌的RMC-6036的潛在成功表現增強了信懇智能，尤其是考慮到最近披露的第10/10億期數據後。
在一次重要科學會議和投資者活動上介紹了胰腺導管腺癌（PDAC）'6236和'9805的最新臨床數據更新後，分析師對'6236的最新第1期數據的改善表示滿意。首次報道的中位總生存率（mOS）數據強化了'6236改變第二線及更廣泛胰腺導管腺癌（PDAC）治療格局的潛力。此外，'9805在PDAC的首次人體試驗（FIH）數據也受到積極評價，展示出具有臨床活性跡象和超出初步預期的安全性概況的潛在跡象。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
